Novo Holdings Leads $100 Million Series C Financing of Asceneuron to Advance Groundbreaking Therapy for Alzheimer's Disease
Novo Holdings Leads $100 Million Series C Financing of Asceneuron to Advance Groundbreaking Therapy for Alzheimer's Disease
- Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer's disease
- Alzheimer's disease is an area of very high unmet medical need with a lack of oral disease modifying therapies
- Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings will join Asceneuron Board of Directors
- 資金將用於推進ASN51領先資產，這是一種口服小分子OGA抑制劑，用於治療阿爾茨海默病的二期臨床實驗發展。
- 阿爾茨海默病是醫療需求非常高，缺乏口服疾病修復療法的領域。
- Naveed Siddiqi，Venture Investments的高級合夥人，Novo Holdings將加入Asceneuron董事會。
COPENHAGEN, Denmark, July 16, 2024 /PRNewswire/ -- Novo Holdings, a leading life science investor, today announces it led a $100 million Series C Financing in Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a driver of neurodegenerative disease. The financing will be used to advance Asceneuron's lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer's disease.
丹麥哥本哈根，2024年7月16日 /新華社/ --領先的生命科學投資者Novo Holdings今日宣佈，其領導的1億美元C輪融資投資Asceneuron，一家臨床階段的生物技術公司，開發針對tau蛋白聚集的小分子藥物，這是神經退行性疾病的驅動因素。資金將用於將Asceneuron的領先資產ASN51推進阿爾茨海默病的二期臨床實驗。
ASN51 is an oral small molecule drug designed to inhibit OGA, an enzyme implicated in tau protein aggregation. By preventing the aggregation of tau proteins, ASN51 aims to slow the progression of Alzheimer's disease. OGA inhibition has also shown promising potential to prevent the aggregation of proteins that are central to other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis.
ASN51是口服小分子藥物，設計用於抑制OGA，這是與tau蛋白聚集有關的一種酶。通過防止tau蛋白的聚集，ASN51旨在減緩阿爾茨海默病的進展。OGA的抑制還顯示出潛在的前景，可以預防與其他神經退行性疾病，包括帕金森病和肌萎縮側索硬化症有關的蛋白聚集。
ASN51's unique mode of action and convenient oral formulation make it an ideal therapy for patients with Alzheimer's disease. Asceneuron has completed five Phase 1 clinical trials, demonstrating complete central nervous system uptake and high OGA enzyme occupancy, indicating its potential for differentiation from its competitors. Asceneuron plans to initiate its first Phase 2 clinical study later this year.
ASN51獨特的作用方式和方便的口服制劑使其成爲阿爾茨海默病患者理想的療法。Asceneuron已經完成了五項一期臨床試驗，證明了完全的中樞神經系統攝取和高OGA酶佔用率，表明其在競爭對手中具有差異化的潛力。 Asceneuron計劃於今年晚些時候啓動其第一項二期臨床研究。
Asceneuron has a seasoned leadership team and a world class Scientific Advisory Board of experts in neurodegenerative diseases.
Asceneuron擁有經驗豐富的領導團隊和世界一流的科學顧問委員會，專門從事神經退行性疾病領域的專家。
Naveed Siddiqi MD, Senior Partner, Venture Investments, Novo Holdings said: "Alzheimer's disease is undergoing a transformational moment. Millions are afflicted by this devastating disease and there are very few therapeutic options. Validated biomarkers are allowing for more focused and rapid development. We are now witnessing the approvals of the first disease modifying antibody based injectable therapies. Asceneuron's innovative oral small molecule drug targeting intracellular tau offers the potential for a paradigm shift in the way this neurodegenerative disease is treated."
Naveed Siddiqi，MD，Venture Investments的高級合夥人，Novo Holdings表示：“阿爾茨海默病正在經歷轉型時刻。數百萬人飽受這種毀滅性疾病之苦，療法極少。已驗證的生物標誌物使得選拔更集中、開發更快捷。我們現在正在見證首批基於抗體的疾病修復注射療法的批准。 Asceneuron創新的口服小分子藥物，針對細胞內tau的靶向提供了潛在的範式轉變，可以治療這種神經退行性疾病。”
In connection with the financing, Naveed Siddiqi will join the Asceneuron Board of Directors.
與融資有關，Naveed Siddiqi將加入Asceneuron董事會。
Barbara Angehrn Pavik, Chief Executive Officer of Asceneuron, commented: "This high caliber life science investor syndicate, led by Novo Holdings, further validates the potential of our OGA inhibitor pipeline and leadership in the field of tauopathies. We are excited to advance our lead asset ASN51 into Phase 2 clinical development, recognizing its potential to significantly expand treatment options for patients with Alzheimer's disease."
Asceneuron首席執行官Barbara Angehrn Pavik評論道：“這家由Novo Holdings領導的高素質生命科學投資者共同投資，進一步驗證了我們OGA抑制劑管道的潛力和在tauopathies領域的領導地位。我們很高興將我們的領導資產ASN51推進阿爾茨海默病的二期臨床發展，認識到它在顯著擴大阿爾茨海默病患者治療選擇方面的潛力。”
The financing was led by Novo Holdings, with additional new investment from EQT Life Sciences Dementia Fund, OrbiMed and SR One, alongside participation from existing investors, M Ventures and Sofinnova Partners.
該融資由Novo Holdings領導，EQt Life Sciences Dementia Fund，OrbiMed和SR One等新增投資者，以及現有投資者萬Ventures和索芬諾瓦合夥人參加。
About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
關於Novo Holdings A/S
Novo Holdings是一家控股和投資公司，負責管理Novo Nordisk Foundation的資產和財富。Novo Holdings的目的是通過對Novo Nordisk Foundation的資產獲得有吸引力的長期回報，從而改善人們的健康以及社會和地球的可持續性。
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health Investments and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.
Novo Holdings是Novo Nordisk A/S和Novonesis A/S（Novozymes A/S）的控股股東，管理具有長期回報前景的投資組合。除了管理廣泛的股票，債券，房地產，基礎設施和私募股權資產組合外，Novo Holdings還是世界領先的生命科學投資者。通過其種子，創業，成長，亞洲，全球計劃衛生投資和主要投資團隊，Novo Holdings投資於生命科學公司的各個發展階段。
As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. .
截至2023年末，Novo Holdings的總資產爲eur 1490億。
About Asceneuron
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The company's pipeline reflects its ambition and commitment to developing treatments for a wide range of neurodegenerative diseases. Asceneuron has two clinical-stage small molecule OGA inhibitors in development: ASN90 (licensed to Ferrer Pharmaceuticals) for the treatment of progressive supranuclear palsy (PSP) and a potential best-in-class molecule, ASN51, for Alzheimer's disease. The company is also planning to advance its pre-clinical development pipeline in Parkinson's disease, amyotrophic lateral sclerosis (ALS) and other neurodegenerative indications. Asceneuron is backed by a renowned syndicate of investors consisting of Alzheimer's Drug Discovery Foundation (ADDF), EQT Life Sciences Dementia Fund, GSK Equities Investments Limited, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners, M Ventures, Novo Holdings, OrbiMed, Sofinnova Partners and SR One. For more information, please visit .
關於Asceneuron
Asceneuron是一家臨床階段的生物技術公司，專注於開發口服可利用的治療極需的神經退變性疾病。該公司的產品線反映了其開發治療各種神經退變性疾病的野心和承諾。Asceneuron有兩種處於臨床階段的小分子OGA抑制劑：ASN90（授權給Ferrer Pharmaceuticals）治療漸進性核上性麻痹（PSP）和ASN51提供阿爾茨海默病最佳潛在分子。該公司還計劃推進其帕金森病、肌萎縮側索硬化症（ALS）和其他神經退行性疾病的臨床前研究管道。Asceneuron得到阿爾茨海默病藥物發現基金(ADDF)、EQt Life Sciences Dementia Fund、GSK Equities Investments Limited、Johnson & Johnson Innovation – JJDC、Inc. (JJDC)、Kurma Partners萬 Venture，Novo Holdings，OrbiMed，索芬諾瓦合夥人和SR One的一流投資者的支持。有關更多信息，請訪問。
SOURCE Novo Holdings
新威集團來源